|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
US8651113B2
(en)
*
|
2003-06-18 |
2014-02-18 |
Swr&D Inc. |
Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
|
|
US20050043239A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Jason Douangpanya |
Methods of inhibiting immune responses stimulated by an endogenous factor
|
|
WO2005016349A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Methods of inhibiting leukocyte accumulation
|
|
ES2437590T3
(es)
|
2004-03-02 |
2014-01-13 |
The Johns-Hopkins University |
Mutaciones del gen de PIK3CA en cánceres humanos
|
|
ES2873875T3
(es)
|
2004-05-13 |
2021-11-04 |
Icos Corp |
Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
|
|
WO2005117889A1
(en)
*
|
2004-05-25 |
2005-12-15 |
Icos Corporation |
Methods for treating and/or preventing aberrant proliferation of hematopoietic
|
|
US20080287469A1
(en)
*
|
2005-02-17 |
2008-11-20 |
Diacovo Thomas G |
Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
|
|
CA2620855A1
(en)
*
|
2005-09-01 |
2007-08-02 |
Beth Israel Deaconess Medical Center |
Wortmannin conjugates and uses thereof
|
|
WO2007035395A2
(en)
*
|
2005-09-16 |
2007-03-29 |
Virginia Commonwealth University Intellectual Property Foundation |
Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors
|
|
EP1962901A2
(en)
*
|
2005-12-01 |
2008-09-03 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Compositions and methods relating to treatment of cancer and infectious diseases
|
|
WO2007092646A2
(en)
*
|
2006-02-09 |
2007-08-16 |
Enzon Pharmaceuticals, Inc. |
Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
|
|
US8329683B2
(en)
*
|
2006-06-02 |
2012-12-11 |
Nexgenix Pharmaceuticals, Llc |
Treatment of neurofibromatosis with radicicol and its derivatives
|
|
WO2007143629A1
(en)
*
|
2006-06-02 |
2007-12-13 |
Nexgenix Pharmaceuticals |
Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
|
|
PE20090717A1
(es)
*
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
EP2231152B1
(en)
*
|
2008-01-24 |
2014-01-01 |
SignalRX Pharmaceuticals, Inc. |
Thienopyranones as kinase inhibitors
|
|
WO2009108704A1
(en)
*
|
2008-02-25 |
2009-09-03 |
Semafore Pharmaceuticals, Inc. |
O-alkylated pi-3 kinase inhibitor prodrug combination
|
|
DE102008001855A1
(de)
*
|
2008-05-19 |
2009-11-26 |
Evonik Degussa Gmbh |
Zweikomponenten-Zusammensetzung zur Herstellung von flexiblen Polyurethan-Gelcoats
|
|
WO2009141823A2
(en)
|
2008-05-22 |
2009-11-26 |
Ramot At Tel Aviv University Ltd. |
Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
|
|
US8524691B2
(en)
|
2008-08-13 |
2013-09-03 |
The Medicines Company |
Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
CA2743642C
(en)
|
2008-11-13 |
2017-09-19 |
Calistoga Pharmaceuticals, Inc. |
Therapies for hematologic malignancies
|
|
US8864627B2
(en)
|
2009-03-17 |
2014-10-21 |
Woodway Usa, Inc. |
Power generating manually operated treadmill
|
|
MX2011009955A
(es)
|
2009-03-24 |
2011-11-18 |
Gilead Calistoga Llc |
Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
|
|
ES2548253T3
(es)
|
2009-04-20 |
2015-10-15 |
Gilead Calistoga Llc |
Métodos para el tratamiento de tumores sólidos
|
|
EP2445343B1
(en)
|
2009-06-25 |
2021-08-04 |
Alkermes Pharma Ireland Limited |
Prodrugs of nh-acidic compounds
|
|
HUE033442T2
(en)
|
2009-06-25 |
2017-11-28 |
Alkermes Pharma Ireland Ltd |
Heterocyclic compounds for the treatment of neurological and psychological disorders
|
|
MX2012000817A
(es)
|
2009-07-21 |
2012-05-08 |
Gilead Calistoga Llc |
Tratamiento para desordenes del higado con inhibidores pi3k.
|
|
US8305582B2
(en)
|
2009-09-01 |
2012-11-06 |
Alltech Associates, Inc. |
Methods and apparatus for analyzing samples and collecting sample fractions
|
|
PT2496567T
(pt)
*
|
2009-11-05 |
2017-11-15 |
Rhizen Pharmaceuticals S A |
Novos moduladores de quinase benzopiran
|
|
JP5848761B2
(ja)
|
2010-06-24 |
2016-01-27 |
アルカーメス ファーマ アイルランド リミテッド |
Nh酸性化合物のプロドラッグ:エステル、カルボネート、カルバメートおよびホスホネートの誘導体
|
|
MX336549B
(es)
|
2010-12-20 |
2016-01-22 |
Glenmark Pharmaceuticals Sa |
Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1.
|
|
EP3156056B1
(en)
|
2011-03-18 |
2023-12-06 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising sorbitan esters
|
|
WO2012137225A1
(en)
*
|
2011-04-08 |
2012-10-11 |
Sphaera Pharma Pvt. Ltd |
Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
|
|
KR20140067070A
(ko)
*
|
2011-08-31 |
2014-06-03 |
말린크로트 엘엘씨 |
H-포스포네이트에 의한 나노입자 peg 개질
|
|
JP5952912B2
(ja)
|
2011-12-15 |
2016-07-13 |
アルカーメス ファーマ アイルランド リミテッド |
二級アミン化合物のプロドラッグ
|
|
BRPI1107182B1
(pt)
*
|
2011-12-29 |
2022-03-08 |
Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig |
Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
|
|
IN2014MN01819A
(OSRAM)
|
2012-03-05 |
2015-07-03 |
Univ Ramot |
|
|
MD20140100A2
(ro)
|
2012-03-05 |
2015-01-31 |
Gilead Calistoga Llc |
Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
|
|
AU2013235523B9
(en)
|
2012-03-19 |
2018-01-04 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising glycerol esters
|
|
AU2013235526B2
(en)
|
2012-03-19 |
2017-11-30 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising benzyl alcohol
|
|
CA2867121C
(en)
|
2012-03-19 |
2021-05-25 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising fatty acid esters
|
|
ES2792149T3
(es)
|
2012-09-19 |
2020-11-10 |
Alkermes Pharma Ireland Ltd |
Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
|
|
WO2014068070A1
(en)
|
2012-10-31 |
2014-05-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
|
EP2986295A4
(en)
|
2013-04-17 |
2016-11-09 |
Biopharma Works |
PROCESS FOR PAIN TREATMENT
|
|
EP2986294A4
(en)
*
|
2013-04-17 |
2016-11-16 |
Biopharma Works |
PROCESS FOR PAIN TREATMENT
|
|
EP3594215A1
(en)
|
2013-12-20 |
2020-01-15 |
Gilead Calistoga LLC |
Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors
|
|
US9708327B2
(en)
|
2013-12-20 |
2017-07-18 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
|
|
CA2940666C
(en)
|
2014-02-28 |
2022-08-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2015140257A1
(en)
|
2014-03-19 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for inducing human cholangiocyte differentiation
|
|
AU2015231278B2
(en)
|
2014-03-20 |
2020-01-23 |
Alkermes Pharma Ireland Limited |
Aripiprazole formulations having increased injection speeds
|
|
NZ726360A
(en)
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
|
CN106715456B
(zh)
|
2014-08-12 |
2023-08-29 |
莫纳什大学 |
定向淋巴的前药
|
|
WO2016065142A2
(en)
|
2014-10-22 |
2016-04-28 |
The Johns Hopkins University |
New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
|
|
SI3215518T1
(sl)
|
2014-10-29 |
2021-08-31 |
Bicyclerd Limited |
Biciklični peptidni ligandi, značilni za MT1-MMP
|
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
US10253052B2
(en)
|
2015-07-07 |
2019-04-09 |
Five Eleven Pharma Inc. |
HBED-bisphosphonates, radiometal conjugates and their use as theranostic agents
|
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
EP3347340A4
(en)
|
2015-09-08 |
2019-01-23 |
Monash University |
LYMPHENLEITUNGSPRODRUGS
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
WO2017062504A1
(en)
|
2015-10-06 |
2017-04-13 |
Woodway Usa, Inc. |
Manual treadmill and methods of operating the same
|
|
RS64114B1
(sr)
|
2015-10-23 |
2023-04-28 |
Navitor Pharm Inc |
Modulatori interakcije sestrin-gator2 i nјihova upotreba
|
|
EP3378869A4
(en)
*
|
2015-11-17 |
2019-09-18 |
Nissan Chemical Corporation |
PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES
|
|
US11370792B2
(en)
|
2015-12-14 |
2022-06-28 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of MTHFD2 and uses thereof
|
|
WO2017156165A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
WO2017162536A1
(en)
|
2016-03-21 |
2017-09-28 |
H. Lundbeck A/S |
Vortioxetine prodrugs
|
|
WO2017175022A1
(en)
|
2016-04-07 |
2017-10-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for inhibiting mast cell degranulation
|
|
EP3440112A4
(en)
|
2016-04-08 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
METHOD FOR THE TREATMENT OF CANCER
|
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
|
WO2017223243A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
EP3478375B2
(en)
|
2016-07-01 |
2024-05-22 |
Woodway USA, Inc. |
Motorized treadmill with motor braking mechanism and methods of operating same
|
|
US10072032B2
(en)
*
|
2016-09-19 |
2018-09-11 |
Afton Chemical Corporation |
AminoBisPhosphonate antiwear additives
|
|
TWI825663B
(zh)
|
2016-10-14 |
2023-12-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
|
AU2017345736B2
(en)
|
2016-10-21 |
2022-04-07 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
|
US10414727B2
(en)
|
2016-11-08 |
2019-09-17 |
Navitor Pharmaceuticals, Inc. |
Phenyl amino piperidine mTORC inhibitors and uses thereof
|
|
CN110177544A
(zh)
|
2016-11-29 |
2019-08-27 |
普尔泰克健康有限公司 |
用于递送治疗剂的外泌体
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
JP2020502238A
(ja)
|
2016-12-23 |
2020-01-23 |
バイスクルアールディー・リミテッド |
新規連結構造を有するペプチド誘導体
|
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
US11760762B2
(en)
|
2017-01-27 |
2023-09-19 |
Signalrx Pharmaceuticals, Inc. |
Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
|
|
JP7160824B2
(ja)
|
2017-03-08 |
2022-10-25 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤、使用およびその製造のための方法
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
|
WO2018199174A1
(ja)
*
|
2017-04-25 |
2018-11-01 |
生化学工業株式会社 |
第3級アミン化合物又はイミン化合物-ポリマーコンジュゲートとその製造方法
|
|
EP4556069A3
(en)
|
2017-04-26 |
2025-08-13 |
Navitor Pharmaceuticals, Inc. |
Modulators of sestrin-gator2 interaction and uses thereof
|
|
EP3615550A1
(en)
|
2017-04-27 |
2020-03-04 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
|
HRP20220790T1
(hr)
|
2017-05-04 |
2022-09-16 |
Bayer Cropscience Aktiengesellschaft |
Derivati 2-{[2-(feniloksimetil)piridin-5-il]oksi}etanamina i srodni spojevi kao pesticidi, primjerice namijenjeni zaštiti bilja
|
|
CN108929329B
(zh)
*
|
2017-05-24 |
2020-12-11 |
中国医学科学院药物研究所 |
2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物
|
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
DK3658557T3
(da)
|
2017-07-28 |
2024-07-29 |
Takeda Pharmaceuticals Co |
Tyk2-inhibitorer og anvendelser deraf
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
EP3668887A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
AU2018324037A1
(en)
|
2017-08-29 |
2020-04-16 |
Monash University |
Lymphatic system-directing lipid prodrugs
|
|
IL322809A
(en)
|
2017-09-22 |
2025-10-01 |
Kymera Therapeutics Inc |
Protein Decomposers and Their Uses
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
CN108003188A
(zh)
*
|
2017-12-25 |
2018-05-08 |
长春吉大天元化学技术股份有限公司 |
一种烷基磷酸酯类化合物的新型纯化方法
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3746071A4
(en)
|
2018-01-29 |
2021-09-01 |
Merck Patent GmbH |
GCN2 INHIBITORS AND THEIR USES
|
|
CN111918651B
(zh)
|
2018-01-29 |
2024-01-30 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
|
WO2019162682A1
(en)
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
JP7317032B2
(ja)
|
2018-02-27 |
2023-07-28 |
アルタックス バイオファーマ インコーポレイテッド |
Tcr-nck相互作用の阻害剤としてのクロメン誘導体
|
|
CA3092335A1
(en)
|
2018-03-05 |
2019-09-12 |
Alkermes Pharma Ireland Limited |
Aripiprazole dosing strategy
|
|
TWI884914B
(zh)
|
2018-04-24 |
2025-06-01 |
美商維泰克斯製藥公司 |
喋啶酮化合物及其用途
|
|
HRP20220710T1
(hr)
|
2018-04-24 |
2022-07-22 |
Merck Patent Gmbh |
Antiproliferacijski spojevi i njihova uporaba
|
|
EA202092692A1
(ru)
|
2018-06-15 |
2021-04-21 |
Навитор Фармасьютикалз, Инк. |
Аналоги рапамицина и их применения
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
WO2020023340A1
(en)
|
2018-07-23 |
2020-01-30 |
Signalrx Pharmaceuticals, Inc. |
Single molecule compounds providing multi-target inhibition of btk and other proteins and methods of use thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
WO2020050378A1
(ja)
*
|
2018-09-06 |
2020-03-12 |
生化学工業株式会社 |
第3級アミン化合物又はイミン化合物を結合させた、ポリマーコンジュゲートとその製造方法
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN113271940A
(zh)
|
2018-10-15 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
EP3870597A1
(en)
|
2018-10-23 |
2021-09-01 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
|
JP7644002B2
(ja)
|
2018-10-24 |
2025-03-11 |
ナビター ファーマシューティカルズ, インコーポレイテッド |
多形化合物およびその使用
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CA3120866A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
WO2020128526A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicycletx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
EP3914357A4
(en)
|
2019-01-23 |
2022-10-12 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND THEIR USES
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
USD930089S1
(en)
|
2019-03-12 |
2021-09-07 |
Woodway Usa, Inc. |
Treadmill
|
|
CA3135569A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
CN113939300A
(zh)
|
2019-04-05 |
2022-01-14 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
|
AU2020282759A1
(en)
|
2019-05-31 |
2021-12-23 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
|
TWI862640B
(zh)
|
2019-07-30 |
2024-11-21 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
US11845724B2
(en)
|
2019-09-11 |
2023-12-19 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
|
BR112022004451A2
(pt)
|
2019-09-13 |
2022-06-21 |
Nimbus Saturn Inc |
Antagonistas de hpk1 e usos dos mesmos
|
|
CN114786660A
(zh)
|
2019-11-01 |
2022-07-22 |
纳维托制药有限公司 |
使用mtorc1调节剂的治疗方法
|
|
KR20220128345A
(ko)
|
2019-12-05 |
2022-09-20 |
아나쿠리아 테라퓨틱스, 인코포레이티드 |
라파마이신 유사체 및 이의 용도
|
|
JP2023509366A
(ja)
|
2019-12-17 |
2023-03-08 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2021159021A1
(en)
|
2020-02-05 |
2021-08-12 |
Puretech Lyt, Inc. |
Lipid prodrugs of neurosteroids
|
|
WO2021178488A1
(en)
|
2020-03-03 |
2021-09-10 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
PH12022552458A1
(en)
|
2020-03-19 |
2024-01-22 |
Kymera Therapeutics Inc |
Mdm2 degraders and uses thereof
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US20240240255A1
(en)
|
2020-08-17 |
2024-07-18 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
US12331046B2
(en)
|
2020-10-23 |
2025-06-17 |
Nimbus Clotho, Inc. |
CTPS1 inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
AU2021392040A1
(en)
|
2020-12-02 |
2023-06-29 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
MX2023007852A
(es)
|
2020-12-30 |
2023-07-07 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
|
CA3206499A1
(en)
|
2021-02-02 |
2022-08-11 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
CA3206501A1
(en)
|
2021-02-02 |
2022-08-11 |
Shaun Abbott |
Gpr84 antagonists and uses thereof
|
|
CN117120090A
(zh)
|
2021-02-12 |
2023-11-24 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
AU2022220869A1
(en)
|
2021-02-15 |
2023-08-24 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
EP4291187A4
(en)
|
2021-02-15 |
2025-01-15 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
JP2024509192A
(ja)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
|
EP4319756A4
(en)
|
2021-04-09 |
2025-02-26 |
Nimbus Clio, Inc. |
CBL-B MODULATORS AND USES THEREOF
|
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
CN117715904A
(zh)
|
2021-05-07 |
2024-03-15 |
凯麦拉医疗公司 |
Cdk2降解剂和其用途
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
CN118103368A
(zh)
|
2021-08-25 |
2024-05-28 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
AU2023214044A1
(en)
|
2022-01-31 |
2024-08-08 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
EP4565564A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
AU2023317740A1
(en)
|
2022-08-02 |
2025-03-13 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
TW202430148A
(zh)
|
2022-11-22 |
2024-08-01 |
美商皮克醫療公司 |
eIF4E抑制劑及其用途
|
|
WO2024264017A2
(en)
|
2023-06-23 |
2024-12-26 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|